ClinicalTrials.gg
CompletedNCT01566604GLOW7Updated Aug 8, 2014Results posted

Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals. Completed at 32 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
22nd of 73
460 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
22nd of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 22nd largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237 in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks treatment.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • NVA237
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults aged ≥40 years, who have signed an Form prior to initiation of any study-related procedure
  • With moderate to severe stable (Stage II or Stage III).
  • Current or ex-smokers who have a smoking history of at least 10 pack years (Ten pack- years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years).
  • Post-bronchodilator ≥30% and \< 80% of the predicted normal, and post-bronchodilator FEV1/FVC \< 0.7 at Visit 2 (Day -14) (post means: record FEV1 and FVC 45 min after administering ipratropium).
  • Symptomatic patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3

Exclusion criteria

Exclusion Criteria:

  • With a history of of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin.
  • Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm3 (at Visit 2) or onset of symptoms prior to age 40 years. Patients without asthma but who have a blood eosinophil count >600/mm3 at Visit 2 are excluded.
  • Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless confirmed by imaging to be no longer active) or bronchiectasis, sarcoidosis and interstitial lung disorder.
  • Patients with lung lobectomy or lung volume reduction or lung transplantation.
  • Patients with known history and diagnosis of α-1 antitrypsin deficiency.
  • Patients who have had a exacerbation that required treatment with antibiotics, systemic (oral or intravenous) or hospitalization in the 6 weeks prior to Visit 1 Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    NVA237

    NVA237 50 µg once daily delivered via a single dose dry powder inhaler

    Drug: NVA237

  • Placebo comparator
    Placebo

    Placebo once daily delivered via a single dose dry powder inhaler

    Drug: Placebo

Interventions

  • DrugNVA237

    Delivered via a single dose dry powder inhaler

  • DrugPlacebo

    Delivered via a single dose dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Trough Forced Expiratory Volume in One Second (FEV1)

    Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.

    Time frame: 12 weeks

Secondary outcomes

  1. Transition Dyspnea Index (TDI) Score

    Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

    Time frame: Baseline, week 12, week 26

  2. Change From Baseline in Daily Rescue Medication Use (Number of Puffs)

    The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.

    Time frame: Baseline, 26 weeks

  3. 24h Trough FEV1

    Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.

    Time frame: Day 1, Week 26

  4. FEV1 and Forced Vital Capacity (FVC)

    FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.

    Time frame: Day 1 at 5, 15, 30 minutes (min) and 1 hour (h) post dose; days 2, 86, 184 at 23 (h) 15 min and 23 h 45 min post dose; days 29, 85, 183 at -45 and -15 min pre-dose and 5, 15, and 30 min post dose

  5. Peak FEV1

    Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.

    Time frame: Day 1, week 12, week 26

  6. Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose

    The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.

    Time frame: Day 1, week 12, week 26

  7. Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)

    In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant's degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.

    Time frame: Baseline, 26 weeks

  8. Time to First Moderate or Severe COPD Exacerbation

    A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.

    Time frame: 26 weeks

  9. Number of Moderate and Severe COPD Exacerbations

    COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.

    Time frame: 26 weeks

  10. The Total Score of the St George's Respiratory Questionnaire (SGRQ)

    SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.

    Time frame: Week 12, week 26

07

Results

Posted Aug 8, 2014

Participant flow

Participants were randomized in a 2: 1 ration to NVA237 and Placebo, respectively.

Participant flow — Overall Study
MilestoneNVA237Placebo
Started306154
Safety set305154
Full analysis set (fas)305154
Fas, serial spirometry subgroup13458
Completed282143
Not completed2411
Withdrew: Patient's inability to use the device10
Withdrew: Administrative problems10
Withdrew: Lack of efficacy12
Withdrew: Protocol deviation20
Withdrew: Abnormal laboratory value20
Withdrew: Death41
Withdrew: Adverse event42
Withdrew: Withdrawal by subject96

Outcome measures

PrimaryTrough Forced Expiratory Volume in One Second (FEV1)

Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.

Time frame:
12 weeks
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in One Second (FEV1)
LitersNVA237Placebo
Trough Forced Expiratory Volume in One Second (FEV1)1.204 ± 0.01351.063 ± 0.0160
SecondaryTransition Dyspnea Index (TDI) Score

Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.

Time frame:
Baseline, week 12, week 26
Reported as:
Least squares mean · score
Transition Dyspnea Index (TDI) Score
scoreNVA237Placebo
week 12 (n=288,141)2.8 ± 0.321.6 ± 0.34
week 26 (n=284,140)3.0 ± 0.312.0 ± 0.34
SecondaryChange From Baseline in Daily Rescue Medication Use (Number of Puffs)

The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · Number of puffs
Change From Baseline in Daily Rescue Medication Use (Number of Puffs)
Number of puffsNVA237Placebo
Change From Baseline in Daily Rescue Medication Use (Number of Puffs)-0.77 ± 0.157-0.55 ± 0.186
Secondary24h Trough FEV1

Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.

Time frame:
Day 1, Week 26
Reported as:
Least squares mean · Liters
24h Trough FEV1
LitersNVA237Placebo
Day 1 (n=289,151)1.230 ± 0.00841.109 ± 0.0104
Week 26 (n=281,143)1.195 ± 0.01401.059 ± 0.0171
SecondaryFEV1 and Forced Vital Capacity (FVC)

FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.

Time frame:
Day 1 at 5, 15, 30 minutes (min) and 1 hour (h) post dose; days 2, 86, 184 at 23 (h) 15 min and 23 h 45 min post dose; days 29, 85, 183 at -45 and -15 min pre-dose and 5, 15, and 30 min post dose
Reported as:
Least squares mean · Liters
FEV1 and Forced Vital Capacity (FVC)
LitersNVA237Placebo
FEV1, day 1, 5 min (n=281,143)1.199 ± 0.00601.112 ± 0.0072
FEV1, day 1, 15 min (n=277,147)1.245 ± 0.00751.116 ± 0.0089
FEV1, day 1, 30 min (n=283,145)1.265 ± 0.00761.111 ± 0.0090
FEV1, day 1, 1 h (n=284,142)1.295 ± 0.00791.124 ± 0.0096
FEV1, day 2, 23 h 15 min (n=267,137)1.228 ± 0.00861.101 ± 0.0108
FEV1, day 2, 23 h 45 min min (n=272,140)1.230 ± 0.00921.107 ± 0.0112
FEV1, day 29, -45 min (n=273,136)1.208 ± 0.01141.079 ± 0.0144
FEV1, day 29, -15 min (n=280,142)1.226 ± 0.01131.097 ± 0.0142
FEV1, day 29, 5 min (n=271,136)1.240 ± 0.01181.097 ± 0.0148
FEV1, day 29, 15 min (n=272,135)1.259 ± 0.01171.103 ± 0.0147
FEV1, day 29, 30 min (n=279,139)1.272 ± 0.01141.105 ± 0.0142
FEV1, day 85, -45 min (n=269,130)1.179 ± 0.01181.050 ± 0.0147
FEV1, day 85, -15 min (n=271,136)1.190 ± 0.01061.052 ± 0.0134
FEV1, day 85, 5 min (n=262,130)1.229 ± 0.01191.059 ± 0.0147
FEV1, day 85, 15 min (n=267,133)1.246 ± 0.01171.061 ± 0.0147
FEV1, day 85, 30 min (n=273,137)1.263 ± 0.01291.077 ± 0.0156
FEV1, day 85, 1 h (n=274,133)1.275 ± 0.01251.079 ± 0.0154
FEV1, day 86, 23 h 15 min (n=261,127)1.195 ± 0.01461.057 ± 0.0175
FEV1, day 86, 23 h 45 min (n=250,132)1.203 ± 0.01381.067 ± 0.0163
FEV1, day 183, -45 min (n=262,135)1.176 ± 0.01481.032 ± 0.0176
FEV1, day 183, - 15 min (n=265,135)1.179 ± 0.01301.052 ± 0.0165
FEV1, day 183, 5 min (n=262,135)1.220 ± 0.01361.055 ± 0.0170
FEV1, day 183, 15 min (n=261,140)1.233 ± 0.01391.070 ± 0.0169
FEV1, day 183, 30 min (n=270,138)1.265 ± 0.01341.071 ± 0.0170
FEV1, day 183, 1 h (n=263,135)1.263 ± 0.01371.075 ± 0.0168
FEV1, day 184, 23 h 15 min (n=263,128)1.197 ± 0.01541.068 ± 0.0188
FEV1, day 184, 23 h 45 min (n=266,132)1.196 ± 0.01441.058 ± 0.0180
FVC, day 1, 5 min (n=281,143)2.925 ± 0.01842.739 ± 0.0220
FVC, day 1, 15 min (n=277,147)2.992 ± 0.02522.759 ± 0.0288
FVC, day 1, 30 min (n=283,145)3.041 ± 0.02352.761 ± 0.0280
FVC, day 1, 1 h (n=284,142)3.044 ± 0.02402.755 ± 0.0286
FVC, day 2, 23 h 15 min (n=267,137)2.953 ± 0.02752.716 ± 0.0326
FVC, day 2, 23 h 45 min (n=272,140)2.981 ± 0.02612.744 ± 0.0311
FVC, day 29, -45 min (n=273,136)2.908 ± 0.03242.690 ± 0.0375
FVC, day 29, -15 min (n=280,142)2.927 ± 0.03122.730 ± 0.0371
FVC, day 29, 5 min (n=271,136)2.970 ± 0.02922.725 ± 0.0353
FVC, day 29, 15 min (n=272,135)2.993 ± 0.02762.751 ± 0.0339
FVC, day 29, 30 min (n=279,139)2.995 ± 0.02872.737 ± 0.0341
FVC, day 85, -45 min (n=269,130)2.854 ± 0.03212.611 ± 0.0385
FVC, day 85, -15 min (n=271,136)2.898 ± 0.03182.627 ± 0.0373
FVC, day 85, 5 min (n=262,130)2.927 ± 0.03212.633 ± 0.0380
FVC, day 85, 15 min (n=267,133)2.954 ± 0.03282.647 ± 0.0387
FVC, day 85, 30 min (n=273,137)2.977 ± 0.03302.695 ± 0.0383
FVC, day 85, 1 h (n=274,133)2.987 ± 0.03472.662 ± 0.0400
FVC, day 86, 23 h 15 min (n=261,127)2.908 ± 0.03662.612 ± 0.0429
FVC, day 86, 23 h 45 min (n=250,132)2.894 ± 0.03602.671 ± 0.0412
FVC, day 183, -45 min (n=262,135)2.858 ± 0.03792.604 ± 0.0430
FVC, day 183, -15 min (n=265,135)2.862 ± 0.03592.633 ± 0.0415
FVC, day 183, 5 min (n=262,135)2.927 ± 0.03682.672 ± 0.0426
FVC, day 183, 15 min (n=261,140)2.957 ± 0.03652.679 ± 0.0420
FVC, day 183, 30 min (n=270,138)2.988 ± 0.03662.707 ± 0.0428
FVC, day 183, 1 h (n=263,135)2.941 ± 0.04012.668 ± 0.0453
FVC, day 184, 23 h 15 min (n=263,128)2.869 ± 0.03862.664 ± 0.0452
FVC, day 184, 23 h 45 min (n=266,132)2.894 ± 0.04022.647 ± 0.0472
SecondaryPeak FEV1

Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.

Time frame:
Day 1, week 12, week 26
Reported as:
Least squares mean · Liters
Peak FEV1
LitersNVA237Placebo
Day 1 (n=134,57)1.376 ± 0.01191.183 ± 0.0146
Week 12 (n=125,56)1.347 ± 0.02071.140 ± 0.0245
Week 26 (n=124,57)1.308 ± 0.02501.112 ± 0.0298
SecondaryStandardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose

The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.

Time frame:
Day 1, week 12, week 26
Reported as:
Least squares mean · Liters
Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose
LitersNVA237Placebo
Day 1 (n=134,57)1.311 ± 0.01221.117 ± 0.0142
Week 12 (n=125,56)1.286 ± 0.02041.080 ± 0.0241
Week 26 (n=124,57)1.243 ± 0.02291.046 ± 0.0280
SecondaryChange From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)

In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant's degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · score
Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)
scoreNVA237Placebo
Total symptom (n=296,150)-1.16 ± 0.143-0.85 ± 0.164
Respiratory symptom-0.21 ± 0.033-0.12 ± 0.038
Cough symptom-0.24 ± 0.030-0.20 ± 0.036
Wheeze symptom-0.30 ± 0.030-0.22 ± 0.036
Sputum production-0.15 ± 0.034-0.11 ± 0.039
Sputum color-0.10 ± 0.025-0.10 ± 0.031
Breathless symptom-0.17 ± 0.030-0.10 ± 0.035
SecondaryTime to First Moderate or Severe COPD Exacerbation

A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.

Time frame:
26 weeks
Reported as:
Median · Days
Time to First Moderate or Severe COPD Exacerbation
DaysNVA237Placebo
Time to First Moderate or Severe COPD ExacerbationNA (NA to NA)NA (NA to NA)
SecondaryNumber of Moderate and Severe COPD Exacerbations

COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.

Time frame:
26 weeks
Reported as:
Mean · Number of exacerbations
Number of Moderate and Severe COPD Exacerbations
Number of exacerbationsNVA237Placebo
Number of Moderate and Severe COPD Exacerbations0.2 ± 0.480.3 ± 0.58
SecondaryThe Total Score of the St George's Respiratory Questionnaire (SGRQ)

SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.

Time frame:
Week 12, week 26
Reported as:
Least squares mean · Score
The Total Score of the St George's Respiratory Questionnaire (SGRQ)
ScoreNVA237Placebo
week 12 (n=293,147)32.35 ± 1.23237.39 ± 1.399
week 26 (n=288,144)31.02 ± 1.48035.94 ± 1.641

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—17/305 (5.6%)81/305 (26.6%)
Placebo—14/154 (9.1%)48/154 (31.2%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventNVA237Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/3059/154
PneumoniaInfections and infestations3/3053/154
Lung infectionInfections and infestations2/3050/154
HypoproteinaemiaMetabolism and nutrition disorders2/3050/154
Respiratory failureRespiratory, thoracic and mediastinal disorders2/3051/154
Pancreatitis acuteGastrointestinal disorders0/3051/154
Lower respiratory tract infectionInfections and infestations0/3051/154
Viral infectionInfections and infestations0/3051/154
Dupuytren's contractureMusculoskeletal and connective tissue disorders0/3051/154
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/3051/154
Most frequent other events
Most frequent other events
EventNVA237Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders49/30532/154
NasopharyngitisInfections and infestations36/30515/154
Upper respiratory tract infectionInfections and infestations18/30512/154

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NVA237PlaceboTotal
Mean64.6 ± 7.8465.0 ± 8.2964.7 ± 7.98
Sex: Female, Male
Sex: Female, Male(Participants)NVA237PlaceboTotal
Female11920
Male294145439
08

Study locations

32 sites
  • Novartis Investigative Site
    Beijing, Beijing 100023, China
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Nanning, Guangxi 530021, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050000, China
  • Novartis Investigative Site
    Changsha City, Hunan 410011, China
  • Novartis Investigative Site
    Nanjing, Jiangsu, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215004, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Shengyang, Liaoning 110016, China
  • Novartis Investigative Site
    Shanghai, Shanghai 200433, China
  • Novartis Investigative Site
    Xi'an, Shanxi 710032, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Chongqing, 400037, China
  • Novartis Investigative Site
    Chongqing, 400038, China
  • Novartis Investigative Site
    Chongqing, 400042, China
  • Novartis Investigative Site
    Guang zhou, 510080, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Dehli, New Delhi 110063, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641 045., India
  • Novartis Investigative Site
    Daejeon, 301-804, Korea, Republic of
  • Novartis Investigative Site
    Incheon, 403-010, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 130-709, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 137-701, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 150-713, Korea, Republic of
  • Novartis Investigative Site
    Bulacan, 3020, Philippines
  • Novartis Investigative Site
    Las Pinas, 1740, Philippines
  • Novartis Investigative Site
    Manila, 1000, Philippines
  • Novartis Investigative Site
    Quezon City, 1100, Philippines
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Mar 29, 2012
Start
Mar 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 8, 2014
Last update
Aug 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01566604
Responsible party
Sponsor
First posted
Mar 29, 2012
Start date
Mar 2012
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 8, 2014
Last update
Aug 8, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion